Clinical and genomic determinants of extraordinary response and resistance to androgen receptor pathway inhibitors in men with metastatic androgen pathway modulator sensitive (APMS) prostate cancer

Prostate Cancer and Prostatic Diseases · Published 2026-08-05 · DOI 10.1038/s41391-026-01145-0

Free full text

Authors (16)

Jane McKenzie, Lauren Howard, Joseph J. Park, Bilal Ashraf, Tara Seibert, Kallie White, Sundhar Ramalingam, Jeffrey W. Shevach, Michael R. Harrison, Christopher Hoimes, Matthew Labriola, Jordan Infield, Dillon Cockrell, Hannah D. McManus, Daniel J. George, Andrew J. Armstrong

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

McKenzie, J., Howard, L., Park, J., et al. (2026). Clinical and genomic determinants of extraordinary response and resistance to androgen receptor pathway inhibitors in men with metastatic androgen pathway modulator sensitive (APMS) prostate cancer. Prostate Cancer and Prostatic Diseases. https://doi.org/10.1038/s41391-026-01145-0

Related articles

• Enzalutamide in metastatic hormone-sensitive prostate cancer: results from the international, multicentre, real-world ARON-3 study · Prostate Cancer and Prostatic Diseases · 2026 · Same journal
• Robot-assisted MRI/US transperineal target prostate biopsy with Biobot Mona Lisa 2.0: first experience in Europe · Prostate Cancer and Prostatic Diseases · 2026 · Same journal
• Systematic profiling of tumor-associated antigen expression for antibody-drug conjugate in prostate cancer · Prostate Cancer and Prostatic Diseases · 2025 · Same journal
• Persistence, progression, and PSA: what exactly does DEAR-EXT compare? · Prostate Cancer and Prostatic Diseases · 2026 · Same journal
• Contrast-free MRI-first screening in young asymptomatic men: Prostate characteristics and cancer detection rates · Prostate Cancer and Prostatic Diseases · 2026 · Same journal
• Prostate biopsy - current discussions and future perspectives · Prostate Cancer and Prostatic Diseases · 2026 · Same journal
• Counseling is counseling is counseling is counseling - The evolution of LUTS/BPO care · Prostate Cancer and Prostatic Diseases · 2026 · Same journal
• Navigating drug–drug interactions with apalutamide · Prostate Cancer and Prostatic Diseases · 2026 · Same journal
• Efficacy of the new P100 extracorporeal shock wave therapy device in the treatment of type IIIB chronic prostatitis/chronic pelvic pain syndrome: a sham treatment controlled, prospective clinical trial · Prostate Cancer and Prostatic Diseases · 2026 · Same journal
• Insights gained from single-cell transcriptomics on the cellular identity and plasticity of prostate epithelial cells · Prostate Cancer and Prostatic Diseases · 2026 · Same journal